May 05, 2017 – This report nicely illustrates how, by both clever study design and selection of according phenotypic patients, genetic predispositions for even very rare serious adverse drug reactions (sARD) can be elucidated, which eventually may lead to theragenomics-based therapy …

Bisphosphonates: GGPS1 Mutation and Atypical Femoral Fractures Read more »

September 01, 2011 – Risk factors for developing renal failure include underlying moderate to severe renal impairment, use of kidney-damaging (nephrotoxic) or diuretic medications at the same time as Zoledronic Acid [Reclast], or severe dehydration occurring before or after Zoledronic …

Drug Safety Communication: Zoledronic Acid [Reclast] Associated with New Contraindication and Updated Warning on Kidney Impairment Read more »

April 15, 2011 – From a press release as of today, we learn the following (text unchanged from  EMEA press release): The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that rare atypical fractures of …

EMEA: Rare atypical fractures of the femur is a class effect of medicines containing bisphosphonates Read more »